C4 Therapeutics financials
$3.13+0.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.6M | $6.2M | $11.0M | $11.2M | $6.5M | $7.2M | $5.2M | $15.4M | $12.0M | $3.0M | $3.3M | $11.1M |
| Gross profit | $6.6M | $6.2M | $11.0M | $11.2M | $6.5M | $7.2M | $5.2M | $15.4M | $12.0M | $3.0M | $3.3M | $11.1M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$26.4M | -$27.8M | -$23.1M | -$34.4M | -$28.5M | -$29.2M | -$37.7M | -$28.2M | -$21.4M | -$32.2M | -$37.4M | -$27.8M |
| Net income | -$23.6M | -$25.1M | -$20.5M | -$32.2M | -$26.0M | -$26.3M | -$34.6M | -$24.7M | -$17.7M | -$28.4M | -$34.8M | -$27.0M |
| Net margin | −355.9% | −408.5% | −186.0% | −286.4% | −402.6% | −363.7% | −667.8% | −160.6% | −147.6% | −933.2% | −1065.7% | −244.2% |
| Diluted EPS | $-0.18 | $-0.20 | $-0.17 | $-0.44 | $-0.37 | $-0.37 | $-0.49 | $-0.35 | $-0.26 | $-0.41 | $-0.68 | $-0.55 |
| EBITDA | -$26.1M | -$27.4M | -$22.7M | -$23.2M | -$27.9M | -$28.7M | -$37.2M | -$27.8M | -$21.0M | -$29.3M | -$37.0M | -$27.4M |
| Operating cash flow | -$1.6M | -$29.9M | -$22.1M | -$31.2M | -$12.1M | -$33.3M | -$17.9M | -$24.1M | -$5.0M | -$18.1M | -$24.0M | -$30.7M |
| Free cash flow | -$1.6M | -$30.0M | -$22.2M | -$31.6M | -$12.2M | -$33.3M | -$17.9M | -$24.1M | -$5.2M | -$18.1M | -$24.2M | -$31.3M |
| Diluted shares | 130.7M | 126.1M | 117.2M | 72.6M | 71.0M | 70.8M | 70.6M | 69.6M | 68.8M | 68.4M | 51.3M | 49.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $78.6M | $61.3M | $74.6M | $58.8M | $78.2M | $51.3M |
| Short-term investments | $175.1M | $174.4M | $173.9M | $133.1M | $136.4M | $163.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $359.4M | $328.9M | $359.1M | $265.5M | $296.5M | $319.5M |
| Total liabilities | $112.1M | $94.6M | $102.5M | $111.1M | $122.5M | $124.4M |
| Shareholders' equity | $247.3M | $234.2M | $256.6M | $154.4M | $174.1M | $195.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology